GENI
NEUTRALGENinCode Provides Update on FDA De Novo Submission
The genetics company provides an update on its FDA submission, indicating ongoing discussions to address outstanding elements identified by the regulator.
GENinCode
1.5500GBX
0.00%
Market Cap
4.45M
Volume
79.07k
12% of avg
P/E Ratio
-0.01
EPS (TTM)
-2
Beta
0.6
Day Range
1.5270p - 1.5750p
52 Week Range
1.0000p1.5500p9.0000p
1.5500p
Upcoming Events
Preliminary Results
GENinCode to provide further update on FDA De Novo submission
High Impact Event
GENI
NEUTRALGENinCode Grants Share Options to Directors
The genetics company has granted share options to its directors and employees as part of an incentive scheme.
GENI
NEUTRALGENinCode Plc Announces Change in Major Shareholding
The diagnostics company announces a decrease in shareholding by a major investor, but the news appears to have no material impact on the business.
GENI
NEUTRALGENinCode Plc Announces Change in Major Shareholding
The diagnostics company has announced a change in major shareholding, with no further details provided.
GENI
NEUTRALGENinCode Plc Announces Change in Major Shareholding
The diagnostics company announces a change in major shareholding, with Dowgate Group Limited acquiring a 7.04% stake.
GENI
BADGENinCode Raises £4.1m in Discounted Retail Offer
The genetics company has raised £4.1 million through a discounted Retail Offer, suggesting low investor appetite and potential underlying challenges.
GENI
NEUTRALGENinCode Raises £4M in Discounted Placing
The healthcare diagnostics company has raised £4 million through a discounted share placing, providing capital but signaling potential ongoing challenges.
GENI
NEUTRALGENinCode Announces Retail Offer as Part of Broader Fundraising
The genetics company announces a retail offer of new shares as part of a broader fundraising, with proceeds to be used for growth and expansion.
GENI
NEUTRALGENinCode Plc Raises £4.0 Million Through Placing and Subscription
The genetics company is raising £4.0 million through a placing and subscription to fund its regulatory and commercialization plans in the US, UK, and Europe.
GENI
GOODGENinCode Expands CARDIO inCode Adoption in US and Spain
The healthcare company announces key milestones for its cardiovascular disease prevention technology, including US reimbursement and Spanish regional launch, positioning it for growth.